Best Agrolife Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Best Agrolife Ltd filed with BSE on 01 Jun 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Best Agrolife reported consolidated FY26 revenue of ₹1,257 crore, down 31% year-on-year, with EBITDA of ₹100 crore and PAT of ₹9 crore, as the agrochemical sector faced unseasonal weather and elevated channel inventory. Q4 FY26 revenue fell 43% year-on-year to ₹156 crore with a negative EBITDA of ₹27 crore, partly due to management's decision to hold back sales during a period of rising raw material costs following geopolitical developments in the Middle East. Management said it implemented two rounds of price increases in April and May 2026 and discussed strategies including new patented and bio-stimulant product launches, working capital reduction, and expansion of B2B technical manufacturing.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Consolidated revenue from operations: ₹1,257 crore (FY26)
p. 4
“For FY26, consolidated revenue from operations stood at ₹1,257 crore as compared to ₹1,814 crore in FY25, reflecting a decline of 31% year-on-year.”
Vikas Jain, page 4 of the filed PDF · View the filing
Gross margin: ₹380 crore (FY26)
p. 4
“Gross margin for the year stood at ₹380 crore as against ₹531 crore in FY25.”
Vikas Jain, page 4 of the filed PDF · View the filing
Gross margin percentage: 30% (FY26)
p. 4
“However, gross margin percentage improved to 30% compared to 29% in the previous year, supported by product mix improvement and calibrated pricing actions.”
Vikas Jain, page 4 of the filed PDF · View the filing
EBITDA: ₹100 crore (FY26)
p. 4
“EBITDA for FY26 stood at ₹100 crore as compared to ₹200 crore in FY25, while EBITDA margin stood at 8% versus 11% in the previous year.”
Vikas Jain, page 4 of the filed PDF · View the filing
Profit After Tax: ₹9 crore (FY26)
p. 4
“Profit After Tax for FY26 stood at ₹9 crore as against ₹70 crore reported in FY25, with PAT margin at 1% compared to 4% last year.”
Vikas Jain, page 4 of the filed PDF · View the filing
Gross margin: ₹35 crore (Q4 FY26)
p. 4
“Gross margin for the quarter stood at ₹35 crore compared to ₹63 crore in the corresponding quarter last year, while gross margin percentage stood at 23% as against 23% in Q4 FY25.”
Vikas Jain, page 4 of the filed PDF · View the filing
EBITDA: negative ₹27 crore (Q4 FY26)
p. 4
“EBITDA for Q4 FY26 stood at negative ₹27 crore compared to negative ₹4 crore in Q4 FY25.”
Vikas Jain, page 4 of the filed PDF · View the filing
PAT: negative ₹37 crore (Q4 FY26)
p. 4
“Profit After Tax for the quarter stood at negative ₹37 crore compared to negative ₹22 crore in Q4 FY25, while PAT margin stood at negative 24% versus negative 8% in the same quarter last year.”
Vikas Jain, page 4 of the filed PDF · View the filing
Inventory levels: ₹651 crore (as of March 31, 2026)
p. 5
“I am pleased to share that inventory levels have reduced significantly from approximately ₹958 crore in FY24 to ₹773 crore in FY25 and further to ₹651 crore as of March 31, 2026.”
Vikas Jain, page 5 of the filed PDF · View the filing
Revenue impact from held-back sales: ₹50–70 crore (Q4 FY26)
p. 5
“While this prudent decision impacted near-term revenues by approximately ₹50–70 crore, we believe it was necessary to protect medium-term profitability and maintain channel discipline.”
Vikas Jain, page 5 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Pricing interventions supporting profitability — Q1 FY27 onward
stated firmly by Vikas Jain
p. 5
“We expect these pricing interventions to progressively support profitability beginning Q1 FY27 onward.”
Vikas Jain, page 5 of the filed PDF · View the filing
New patented product launches — Fluzam, Midcotin, Cubax Power Extra, and Trishanku · FY27
stated firmly by Surendra Sai
p. 3
“FY’27 will see us launch Fluzam, Midcotin, Cubax Power Extra, and Trishanku.”
Surendra Sai, page 3 of the filed PDF · View the filing
Sales return percentage — less than 20% · next year
stated as an aspiration by Vikas Jain
p. 14
“Presently we are at around 20-21% of sales return and we are pretty comfortable at this and continuing we will try to go down less than 20% for the next year.”
Vikas Jain, page 14 of the filed PDF · View the filing
Overall business performance — next year
stated as an aspiration by Vikas Jain
p. 12
“So, obviously we are spending a little higher on the marketing and the numbers sometimes might not describe what efforts we are doing.”
Vikas Jain, page 12 of the filed PDF · View the filing
Q1/near-term turnover and profitability — Q1 FY27
stated firmly by Vikas Jain
p. 14
“So, yes, both with respect to top line as well as bottom line, you will see better numbers because already the prices have been increased and the placements which have started are near prices.”
Vikas Jain, page 14 of the filed PDF · View the filing
New molecule production ramp-up — Q2 or Q3
stated as an aspiration by Surendra Sai
p. 13
“We hope to accelerate the production of these new molecules forward into Q2 or into Q3.”
Surendra Sai, page 13 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management cited new bio-stimulant products, new patented products, nano-urea development, distribution network consolidation, and pricing agility as key levers, alongside monitoring the Gulf conflict and El Nino risk.
Answered by Surendra Sai
Asked by Sucrit D. Patil: What strategic levers are being prioritized to expand the crop protection portfolio, strengthen distribution and manage risks?
p. 6
“We do know that the probability of the El Nino becoming significant is 4th October where potentially there will be a 2 degree plus increase in the El Nino and this would impact the Rabi season.”
Surendra Sai, page 6 of the filed PDF · View the filing
CFO said capex has been postponed, R&D spending continues at about 1% of revenue, two rounds of price increases were implemented, and additional government funding is being sought for liquidity.
Answered by Vikas Jain
Asked by Sucrit D. Patil: What capital allocation and risk management frameworks are being applied to balance working capital and R&D funding, and hedge against raw material volatility?
p. 7
“So, we have done 2 rounds of price increase.”
Vikas Jain, page 7 of the filed PDF · View the filing
Management said roughly 60-65% of sales are produced in-house, with B2B not being purely trading.
Answered by Vikas Jain
Asked by Komal: How much of sales come from own manufacturing versus B2B/trading?
p. 7
“So, as of today almost between 60-65% of our sales are being produced in our own factories.”
Vikas Jain, page 7 of the filed PDF · View the filing
Management said branded gross margin is around 40% versus 15-20% for B2B, with longer inventory and receivable cycles for branded business.
Answered by Surendra Sai
Asked by Komal: What are the margins and working capital cycles for branded versus institutional business?
p. 9
“For branded depending upon product but since our portfolio of patent is going up, we are on an average at around 40% whereas on the B2B we are at around 15-20%.”
Surendra Sai, page 9 of the filed PDF · View the filing
Management said bank facility utilization is at 85-90% with some headroom remaining and government funding support is being pursued, and highlighted a positive operating cash flow for the year.
Answered by Vikas Jain
Asked by Komal: Given high receivables and reliance on bank funding, is the company considering a rights issue or fundraise?
p. 11
“So, I had a positive cash flow last year as well.”
Vikas Jain, page 11 of the filed PDF · View the filing
CFO declined to give a specific numeric guidance but said the difficult phase should be over and next year should be better.
Answered by Vikas Jain
Asked by Varun Sharma: Why has the company repeatedly missed guidance, and what is the guidance for next year?
p. 12
“But yes, what we feel is that the difficult phase should be over this year and next year should be obviously a better number.”
Vikas Jain, page 12 of the filed PDF · View the filing
Management said both top line and bottom line should improve given price increases already implemented.
Answered by Vikas Jain
Asked by Saket Kapoor: How will the deferred sales from March translate into next quarter's numbers?
p. 14
“So, yes, both with respect to top line as well as bottom line, you will see better numbers because already the prices have been increased and the placements which have started are near prices.”
Vikas Jain, page 14 of the filed PDF · View the filing
Management said sales returns fell from 20-30% historically to around 20-21%, and that holding back ₹50-70 crore of sales cost roughly ₹20-23 crore of profit.
Answered by Vikas Jain
Asked by Saket Kapoor: How has the sales return percentage evolved and what caused the Q4 loss magnitude?
p. 14
“So, earlier we were close to 20-30% of sales return.”
Vikas Jain, page 14 of the filed PDF · View the filing
Risks flagged
Unseasonal weather and adverse monsoon conditions impacting key crop segments
p. 2
“The weather was unseasonal throughout the year with some areas experiencing lower than expected rainfall while other areas experienced floods.”
Surendra Sai, page 2 of the filed PDF · View the filing
Gulf conflict driving up solvent and formulation prices
p. 6
“Now, the two key risks which are going to impact not just the agricultural sector, agrochemical and agricultural sector are the Gulf conflict which is still dragging on after approximately 89 days.”
Surendra Sai, page 6 of the filed PDF · View the filing
Potential El Nino impact on the Rabi season
p. 6
“The second aspect which is a major risk that we see in this particular year is the effect of the El Nino.”
Surendra Sai, page 6 of the filed PDF · View the filing
Counterfeit products affecting popular brands
p. 3
“We are experiencing a surge in counterfeits especially for our popular products such as Ronfen.”
Surendra Sai, page 3 of the filed PDF · View the filing
Elevated channel inventory and weak dealer liquidity
p. 4
“FY26 was an exceptionally challenging year for the agrochemical industry, impacted by adverse climatic conditions, uneven pest incidences, elevated channel inventory levels, weak dealer liquidity, and volatility in raw material prices.”
Vikas Jain, page 4 of the filed PDF · View the filing
Sharp raw material price increases following Middle East geopolitical developments
p. 4
“The fourth quarter was particularly impacted by weaker seasonal demand, slower channel liquidation, elevated inventory at the distributor level, and sharp increases in raw material prices during March following geopolitical developments in the Middle East.”
Vikas Jain, page 4 of the filed PDF · View the filing
Dependence on China for certain raw materials
p. 8
“Some of the raw materials are certainly imported from China because India's chemical industry is not yet geared up to be able to supply all raw materials and that's where to a certain extent our imports come into picture.”
Surendra Sai, page 8 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.